Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    Early Weight Loss Linked to Lower Gastroesophageal Junction Carcinoma Survival Rates
    source: pixabay.com

    Early Weight Loss Linked to Lower Gastroesophageal Junction Carcinoma Survival Rates

    Unintended weight loss is a symptom associated with many different forms of cancer. But what can this weight loss tell researchers about the patients and their outcomes? Healio shares a…

    Continue Reading Early Weight Loss Linked to Lower Gastroesophageal Junction Carcinoma Survival Rates
    InformedDNA, Foundation Fighting Blindness Partnership Will Screen Patients for Usher Syndrome, RP Clinical Trials
    source: pixabay.com

    InformedDNA, Foundation Fighting Blindness Partnership Will Screen Patients for Usher Syndrome, RP Clinical Trials

    ProQR Therapeutics is working to develop unique therapeutic solutions for genetic eye diseases. Currently, the company is evaluating its therapeutic candidate ultevursen within the Phase 2/3 Sirius and Celeste clinical trials; you can read…

    Continue Reading InformedDNA, Foundation Fighting Blindness Partnership Will Screen Patients for Usher Syndrome, RP Clinical Trials
    First Patient Dosed in WU-CART-007 Trial for Acute Lymphoblastic Leukemia
    https://unsplash.com/photos/tV-RX0beDp8

    First Patient Dosed in WU-CART-007 Trial for Acute Lymphoblastic Leukemia

    Each year, an estimated 11,000 people across the globe are diagnosed with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL). However, there is only one…

    Continue Reading First Patient Dosed in WU-CART-007 Trial for Acute Lymphoblastic Leukemia
    ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer
    source: pixabay.com

    ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer

    In late February 2022, biopharmaceutical company Trascenta Holding Limited ("Trascenta") provided an update on its clinical program for TST001, a monoclonal antibody therapy designed for those with locally advanced or…

    Continue Reading ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer
    MuSK-CAART for MG Earns Fast Track Designation
    source: pixabay.com

    MuSK-CAART for MG Earns Fast Track Designation

    Currently, there are few effective therapeutic options for patients with MuSK antibody-positive myasthenia gravis (MG). A majority of those with MG have autoantibodies targeting the acetylcholine receptor. As a result, acetylcholinesterase…

    Continue Reading MuSK-CAART for MG Earns Fast Track Designation
    Young Adults Diagnosed with Late-Stage Colorectal Cancer at Rising Rates
    Source: https://pixabay.com/en/dark-building-young-abandoned-boy-1283752/

    Young Adults Diagnosed with Late-Stage Colorectal Cancer at Rising Rates

    In the past, some research has suggested that earlier screening for colorectal cancer – also known as rectal or colon cancer – could be beneficial for improving patient outcomes. For…

    Continue Reading Young Adults Diagnosed with Late-Stage Colorectal Cancer at Rising Rates
    New Test Quickly Identifies CSF Leak
    https://pixabay.com/en/technology-robot-human-hand-2025795/

    New Test Quickly Identifies CSF Leak

    What do MRIs of the head and spine, CT scans of the head with contrast dye, CT myelograms of the spine, and radioisotope tests all have in common? These are…

    Continue Reading New Test Quickly Identifies CSF Leak